Genomma Lab Internacional (GNMLF) Stock Price, News & Analysis

Company Overview

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and sexual improvement, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, and infant nutrition. The company was incorporated in 1996 and is based in Mexico City, Mexico.

Key Stats

• Today's Range: $1.43 to $1.43
• 50-Day Range: $1.26 to $1.43
• 52-Week Range: $0.79 to $1.43
• Volume: N/A
• Average Volume: 7,289 shs
• Market Capitalization: N/A
• P/E Ratio: 0.84
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Genomma Lab Internacional Stock Analysis - MarketRank™

Genomma Lab Internacional scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Genomma Lab Internacional.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genomma Lab Internacional is 0.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.31.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genomma Lab Internacional is 0.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.90.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Genomma Lab Internacional has a short interest ratio ("days to cover") of 22829, which indicates bearish sentiment.

Change versus previous month

Short interest in Genomma Lab Internacional has recently decreased by 16.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genomma Lab Internacional does not currently pay a dividend.

Dividend Growth

Genomma Lab Internacional does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Genomma Lab Internacional has a short interest ratio ("days to cover") of 22829, which indicates bearish sentiment.

Change versus previous month

Short interest in Genomma Lab Internacional has recently decreased by 16.18%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Genomma Lab Internacional this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genomma Lab Internacional insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 36.55% of the stock of Genomma Lab Internacional is held by institutions.

GNMLF Stock Analysis - Frequently Asked Questions

How have GNMLF shares performed this year?

Genomma Lab Internacional's stock was trading at $1.27 on January 1st, 2025. Since then, GNMLF shares have increased by 12.6% and is now trading at $1.43.
View the best growth stocks for 2025 here.

How do I buy shares of Genomma Lab Internacional?

Shares of GNMLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 3/12/2025
• Next Earnings (Estimated): 4/22/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GNMLF
• CIK: N/A
• Web: www.genommalab.com
• Phone: 525550810000
• Fax: N/A
• Employees: 1,614
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 0.84
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A